Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 54Recurrence 5Neoplasms, Plasma Cell 3Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 2Renal Insufficiency 1Plasmablastic Lymphoma 1Kidney Failure, Chronic 1Corneal Diseases 1

Interventions

Etoposide 6Vincristine 5Prednisone 5Doxorubicin 5Cyclophosphamide 5Rituximab 4prednylidene 3deltacortene 3daratumumab 2Cytarabine 2varlilumab 1pomalidomide 1merphos 1ixazomib 1carmustine, poliferprosan 20 drug combination 1belantamab mafodotin 1Vorinostat 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Hydrocortisone 1Disulfides 1Dexamethasone 1Carmustine 1CT-P10 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmablastic Lymphoma × belantamab mafodotin × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡